The core mission of the US Food and Drug Administration’s (FDA) inspections program, as well as how it prioritizes inspections, has remains unchanged despite recent leadership changes at the agency, ...
Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — In the year-plus since ...
The Education Department is advancing its plans to eliminate itself, attempting a work-around to move certain mandatory programs to other federal agencies in a move resulting in considerable confusion ...
The U.S. Department of Education said Tuesday it’s developed six agreements to send many of its key functions to other federal agencies. A majority of the Education Department’s funding for K-12 ...
Recursion Pharmaceuticals doesn't have any products on the market. In fact, none of the company's candidates are currently in phase 3 studies. So, despite the biotech's claims that its AI-powered ...
Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...
RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. The analyst who called NVIDIA in 2010 just named his top ...
The brain is the “control center” of the body. Together with the spinal cord, it makes up the central nervous system. Various parts of the brain are responsible for movement, breathing, and other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results